NeuroPharm, Inc.™ (NPI), a division of Mydecine Innovations Group based in Canada, announced it was beginning the first-of-its-kind clinical trials using psilocybin-assisted therapy for treating PTSD (post-traumatic stress disorder) in Veterans. In an interview with Forbes, NPIs scientific advisor, Dr. Rakesh Jetly, explained that clinical trials have been conducted studying MDMA for treating depression, but there are a lack of studies examining psilocybin for treating PTSD. Dr. Jetly added, “There is evidence that veterans are particularly hard to treat with conventional evidence-based therapies, which increases the need for novel therapies that are safe and effective.”